Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab

University of Sao Paulo

Overview

Purpose: To evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure (IOP) variations after intravitreal bevacizumab injection (IVBV). Methods: 47 patients scheduled for IVBV (1.5 mg / 0.06 ml) will be randomly assigned to a pre-treatment 1 hour before IVBV with either 250 mg oral acetazolamide (DIA, 9 eyes), anterior chamber paracentesis immediate after IVBV (PAR, 15 eyes), topic brimonidine tartarate 1 hour before IVBV (BRI, 14 eyes), or no pre-treatment IBVB (CTR, 9 eyes). IOP will be measured 90 minutes before injection (baseline), just before injection, and at 3, 10, 20 and 30 minutes after the procedure.

Study Type

INTERVENTIONAL

Conditions

Macular Edema Diabetic Retinopathy Macular Degeneration

Interventions

bevacizumabDRUG

anterior chamber paracentesisPROCEDURE

acetazolamideDRUG

brimonidineDRUG

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * macular edema Exclusion Criteria: * pulmonary chronic problems * chronic renal failure * intraocular inflammation * drug or alcohol addiction

Locations (1)

School of Medicine - Clinical Hospital

Ribeirão Preto, São Paulo, Brazil

Outcomes

Primary Outcomes

Intra-ocular pressure variation after intra-vitreous injection of bevacizumab

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.